Abstract. In this study the substantial and in part contradictory data available in the literature was collected concerning the frequency of small supernumerary marker chromosomes (sSMC) in the human population in general, and in special subpopulations. One hundred and thirty-two studies on sSMC were reviewed. In summary 1,288,693 cytogenetically studied cases detecting 980 sSMC were compiled. In 132 international surveys there were no ethnic effects detected in the sSMC frequency. sSMC were present in 0.075% of unselected prenatal cases but only in 0.044% of consecutively studied postnatal ones. In infertile subjects, 0.125% were sSMC carriers, distinguishing male from female subjects by a 7.5:1 difference in sSMC frequency for this special group. In developmentally retarded patients the sSMC rate was elevated to 0.288%, similar to prenatal cases with ultrasound abnormalities (0.204%). No increased risk for the presence of sSMC was detected in ICSI-induced pregnancies. Worldwide there are ~2.7x10 6 living sSMC carriers; 1.8x10 6 have a de novo sSMC and ~70% of those are clinically normal. Strikingly, 30-50% of pregnancies diagnosed with an sSMC fetus are terminated. This may be connected with the empirical risk that ~30% of sSMC carriers manifest clinical abnormalities. Thus, in summary there is a strong need for a better genotype-phenotype correlation enabling better genetic counseling.
Introduction
Small supernumerary marker chromosomes (sSMC) were recently defined as structurally abnormal chromosomes that cannot be identified or characterized unambiguously by conventional banding cytogenetics alone; they are generally equal in size or smaller than a chromosome 20 of the same metaphase spread. If detected in banding cytogenetics they are still a major problem as they are too small to be considered for their chromosomal origin by traditional banding techniques; molecular cytogenetic techniques are needed for their characterization (1) . The risk for an abnormal phenotype in prenatally ascertained de novo cases with sSMC is given as ~13% (2) . This has been refined to 7% (for sSMC from chromosome 13, 14, 21 or 22) and 28% (for all non-acrocentric autosomes) (3) and recently has been suggested to be 26% (4) . Thus, the statement of Paoloni-Giacobino et al (5) is still valid, i.e. cases with a de novo sSMC, particularly prenatally ascertained ones, are not easily correlated with a clinical outcome, even though first approaches in that direction were recently attempted (6) . With respect to current technical developments in molecular cytogenetics, such as cenM-FISH techniques (7) (8) (9) and molecular genetic approaches as array-CGH, (10) , further progress in this clinically important field is expected.
However, an important, but not yet thoroughly discussed and understood basic issue is the frequency of sSMC in prenatal as well as in postnatal cases and in patients with infertility or with developmental and/or mental retardation. Here we address this question by reviewing 132 suited datasets derived from the literature as well as from our own laboratory.
Materials and methods
We recently collected all the literature on sSMC and made it available on the sSMC homepage (11) . Based on this collection we presented the available literature from which conclusions on sSMC frequency in different human subpopulations can be drawn. Data from 132 studies with a total of 1,288,693 cytogenetically studied cases detecting 980 sSMC were assembled (Tables I-IV) .
According to the cytogenetic definition of an sSMC (1) also cases i(18p), der (22) , i(12p) and inv dup (22) were counted as sSMC, if listed separately in any of the 132 included studies.
In summary, 1,074,421 prenatal cases were included in Tables IA and B. In Table IA only unselected prenatal cases (688,030) and in Table IB three types of pre-selected cases were incorporated, i.e. 386,391 cases reporting only de novo aberrations, 4,409 cases selected due to ultrasound abnormalities and 4,625 cases born after ICSI treatment.
In Table IIA , 121,694 consecutive newborn individuals from 10 studies were summarized. Table IIB shows the only available study on 1,405 unselected normal adult cases. Table I . sSMC frequency in prenatal cases.
-----------------------------------------------------------------------------------------------------
A, Consecutively collected prenatal cases. 
Forty-one studies on prenatal cases detecting 514 sSMC in 688,030 cytogenetic cases are summarized here. n.a., not available for all sSMC cases reported.
- Tables III and IV summarize 69 ,332 developmentally and/or mentally retarded patients and 30,510 patients with infertility problems, respectively.
In Table V cases already listed in Table I and II were analyzed for the frequency of de novo and inherited sSMC.
Results
The goal of this paper was to give an approximate rate of sSMC cases expected in four main groups of patients: prenatal, postnatal, developmentally and/or mentally retarded and infertile people.
Apparent from Tables I-V the study sizes as well as the detection rates of sSMC varied in all reviewed subgroups; between 15 (12) and 377,357 cases (2) and 0 (12,13) and 162 sSMC carriers (2), respectively. The included cases were studied in time frames between 0.5 (14) and 23 years (15) .
Here and in Tables I-V as well as in Figs. 1 and 2 the results for the four aforementioned groups are listed.
Group 1: Prenatal cases.
In routine prenatal diagnostics 688,030 cases provided by >240 laboratories, including our own detected in summary 514 sSMC (Table IA) . The datasets, which were acquired in 20 different countries indicated a frequency of 0.075% of sSMC in unselected prenatal cases. As summarized in Tables VA and B the detection rate was the same, independent if chorion villi samples (CVS) or amniotic fluid cells (AFC) were studied (Fig. 1) . According to study 42 the rate of de novo sSMC was 0.043%; studies 7 and 43-49 indicated an enhanced sSMC rate of 0.204% in ultrasound-abnormal cases, and in 4.625 ICSI cases (studies 50-62) 2 sSMC were detected (0.043%) (Table IB) .
Group 2: Postnatal cases. In Table IIA we compiled ten newborn studies, to determine the sSMC frequency in the general living human population. Only studies on consecutively newborn children, without further selection criteria were included. In 12,694 postnatal subjects, 54 sSMC cases were described, corresponding to a rate of 0.044% of Table I . Continued. 
In summary 22 studies on three pre-selected subpopulations of prenatal diagnostics detecting only de novo sSMC or looking for sSMC in ICSI or in ultrasound abnormal prenatal cases.
c Twin pregnancy, both twins had sSMC -familial.
-
sSMC carriers in the general population. In study 73, 1,405 normal probands were cytogenetically analyzed and 1 sSMC carrier was identified (Table IIB) .
Group 3:
Developmentally retarded patients. Twenty-six studies provided 69,332 developmentally retarded patients and 200 sSMC carriers were identified, i.e. a rate of 0.288% (Table III) .
Group 4:
Patients with fertility problems. Forty-one cytogenetic studies on a total of 30,510 patients with different fertility problems were available. In general a rate of 0.125% sSMC carriers was detected. When analyzing the dataset of Table IV in a gender-specific manner, the picture changes; i.e. 36/21,841 (0.165%) male and 2/9,165 (0.022%) woman sSMC carriers were found. In Table VA -C also the rate of de novo and familial sSMC was determined based on the studies listed in Tables IA  and IIA . According to the studies in which pertinent data was available, de novo sSMC constituted ~70% and familial, 30% of the cases (Fig. 2) .
Discussion
The frequency of sSMC carriers was given in the literature normally by citing 1-3 more or less randomly selected population studies, most frequently those of Hook and Hamerton (16), Hook and Cross (17), Sachs (18), Warburton (2), Brondum-Nielsen and Mikkelsen (19) and Hsu et al (20) . Thus, the sSMC frequency was normally presented as between 0.028% and 0.150%. 722   Table II . - 
LIEHR and WEISE: DEVELOPMENTALLY RETARDED AND INFERTILITY DIAGNOSTICS
Tawn and Earl, 1992 (87)
Only one small study was available on sSMC frequency in normal adult humans.
- (Table IA) , in ultrasound abnormal and in ICSI-induced pregnancies (Table IB) are shown i n comparison to sSMC frequencies in newborn, infertile and developmentally retarded subjects.
These variations are mainly caused by the studied population size and the bias a single study can be subjected to. The prenatal, as well as the postnatal studies included data worldwide, as detailed in Tables I and II in the category 'Country study performed in'. As countries such as Australia, Canada and the USA included people from Asian, African, Australian and European descent, all ethnic groups were represented in the studies. Moreover, different European, Egyptian, Japanese, Korean and Chinese studies were also included. For example, five studies performed in Germany, a country with a relatively homogeneous population showed variations between 0.042% and 0.225% of the detection rate for prenatal sSMC (Table I, studies 10, 16, 19, 29 and 39 ). An ethnic effect in sSMC frequency was not detected, at least not on the available sample size.
Here we attempted to ascertain the frequency of sSMC carriers in the general population and in some subpopulations.
As some well-recognized and frequently cited previous studies (2, 21) summarized data from different laboratories in similar ways to us, the present attempt to compile patient data from 132 studies in 4 different main groups: prenatal, postnatal, developmentally and/or mentally retarded and infertile seemed to be legitimate and straight forward. However, during this review we encountered problems 
Twenty-six studies provided data for sSMC frequency in developmentally retarded patients.
- Table V . The rate is more or less always 2:1.
concerning the comparability of the research papers included. Especially for the prenatally analyzed cases (Table I) Tables IA and IIA was extracted, and the relevant studies were included in Table VA-C. Another problem was that datasets of some of the studies included in Tables I-IV were repeatedly published in an Table IV . Patients with fertility problems. Male  Female  Total  Male  Female  Total ( 
a ----------------------------------------------------------------------------------------------------------------No. of study Reference Number of studied cases Cases with sSMC -----------------------------------------------------------

%) ---------------------------------------------------------------------------------------------------------------
022% ----------------------------------------------------------------------------------------------------------------
a sSMC frequency in patients with fertility problems was found to be on average 0.125%, but 0.165% for male and 0.022% for female subjects. n.a., not available for all sSMC cases reported. Table V. Excerpt of Tables I and II concerning the frequency and the parental origin of sSMC in CVS, AFC and blood of newborn cases.
----------------------------------------------------------------------------------------------------------------
-----------------------------------------------------------------------------------------------------
A, Parental origin of sSMC in CVS. Familial  --------------------------------------------------------------------------------------------------------------- 
----------------------------------------------------------------------------------------------------------------No. of study Reference Studied cases Cases with sSMC Parental origin of sSMC -------------------De novo
041% ----------------------------------------------------------------------------------------------------------------
a AFC cases were excluded; b AFC cases and fetal blood cases were excluded; c two cases with unknown parental origin. n.a., not available for all sSMC cases reported.
----------------------------------------------------------------------------------------------------------------
B, Parental origin of sSMC in AFC. 'overlapping' way in several papers, e.g. some data available in Nielsen and Wohlert (22) was previously reported in Nielsen and Rasmussen (23) . Thus, one had to be extremely careful not to include the same data twice, especially, as in some publications not very detailed and/or comprehensive references were given on previously published data. To the best of our knowledge we avoided the double use of identical, but repeatedly published data in all Tables. The last and maybe most critical point concerning the comparability of the studies included in Tables I-IV is that when all these studies were performed, no uniform definition of an sSMC was available. Thus, apart from the study of Warburton (2), it was hard if not impossible to know if an sSMC included or excluded isochromosomes 9p, 12p, 18p or Pallister-Killian syndrome and Cat-eye-or der(22)-syndrome chromosomes. While isochromosomes 9p are not sSMC according to the definition of Liehr et al (1) , the other ones are. However, this point was not clarified and was also never questioned in the previous studies included in Tables I-IV. The presence of sSMC was only one of many different cytogenetic aberrations listed in these studies, and for each author/ author group there was no question as to what an sSMC wasit seemed clear to them and thus required no closer reflection.
According to the data from ten consecutive, completely unselected newborn studies (Table IIA) , a rate of 0.044% of sSMC carriers was determined in the general living newborn population. With an estimated human world population of 6,560,000,000 people there are at present ~2.7x10 6 living sSMC carriers.
As previously described (1), the sSMC rate is ~7x higher in (develop)mentally retarded patients (Table III) than in the normal population. This is similar, as we will discuss later, for the prenatal cases with ultrasound abnormalities, not surprising due to the fact that patients with i(12p), i(18p), i(22), der(22) but also larger inv dup (15) are overrepresented in this clinical group.
Patients with fertility problems (Table IV) have a ~2.9x enhanced risk for an sSMC compared to the general population. To note, the rate of sSMC carriers in males versus females was 7.5:1. This observation was biased by heterogeneous reasons which led to the likely inclusion into the group of 'infertility patients' which were studied cytogenetically. However, the rate of male versus female sSMC carriers is strikingly different; and if valid, the mechanisms why an sSMC leads predominantly to male fertility problems have not been eludidated as yet. However, there are hints that oligozoospermia is significantly correlated with sSMC presence in 7% of subjects, while in azoospermia patients, sSMC is present in <1% of the corresponding cases (24) . These observations also fit the recently outlined fact that familial sSMC are predominantly inherited via the maternal line (25) .
According to the data reviewed here, sSMC are to be expected in 0.075% of all analyzed prenatal cases. There was no difference in the sSMC rate in CVS compared to AFC (Table VA and B) . Thus, it can be carefully concluded that there seems to be no significant loss of pregnancies in connection with sSMC between weeks 10-14 (analysis of CVS) compared to weeks 9-15 (analysis of AFC).
Information on the parental origin in 9,705 CVS, 12,2051 AFC and 13,908 newborn cases was available (Table V) . The rate of familial versus de novo cases is 1:2 in all three groups (Fig. 2) . Consequently the rate of familial sSMC cases of 30% is significantly lower compared to the previously suggested value of ~40% (reviewed in ref. 1). This data is also supported by the study of Hume et al (26) , which could not be included in Table V due to the lack of data; they report that out of 19 sSMC cases only 5 were inherited, i.e. 26.3%.
The most cited and extensive prenatal study of Warburton (2) accounting for an sSMC frequency of 0.043% of de novo cases was based on a pre-selected collection, as i) she Table VB . Continued. ---------------------------------------------------------------------------------------------------------------- d Prenatal CVS were excluded; e prenatal CVS and fetal blood cases were excluded. n.a., not available for all sSMC cases reported.
- --------------------------------------------------------------------------------------------------------------- C, Parental origin of sSMC in the blood of newborn cases. 
reported exclusively de novo (sSMC) cases while all other studies did not distinguish de novo and familial sSMC, and ii) she did not include extra chromosomes of identified origin, i.e. all cases with isochromosomes 9p, isochromosomes 18p, Pallister-Killian-, Cat-eye-and der(22)-syndrome chromosomes. So in summary, she underestimated the sSMC frequency in prenatal diagnostics compared to the other studies due to her inclusion criteria. Thus, her study was listed in Table IB together with the other pre-selected cytogenetic studies in prenatal diagnostics: those with detectable ultrasound abnormalities and those after induction of the pregnancy by ICSI. There was a strong positive correlation of sSMC presence and ultrasound abnormalities (Table IB) . With 0.204% this rate was ~2.7x higher than in the general prenatal population. As well known syndromes such as Pallister-Killian, Cat-Eye, i(18p) or der (22) were included here, which normally are connected with malformations, this observation was not unexpected. For ICSI-induced pregnancies only 2 sSMC carriers among 4,625 cytogenetically studied newborns were observed. With a rate of 0.043% this was 1.7x less frequent than in all of the prenatally studied cases of Table IA . However, with high probability this observation was caused by the 146-fold smaller sample size available for ICSI pregnancies compared to all others (Table IA) . In the prenatal study of Karaman et al (27) (study 33 in Table IA) , 4 of 20 reported sSMC cases were ICSI-induced pregnancies; 1 familial case and three de novo sSMC cases were described. Unfortunately, no data is provided in this study as to how many ICSI-induced pregnancies were studied at all. Thus, at present a more or less identical rate of sSMC presence in ICSI-induced compared to a normal newborn population is to be suggested.
The sSMC rate in newborns (Table IIA) of 0.044% was only almost half of the prenatally detected one ( Table IA) and highlights that, in prenatal diagnostics, only a preselected human subpopulation was studied. Concluding, the rate of 0.075% of sSMC carriers in prenatal studies was biased by three main points which were already discussed by Blennow et al (28) : a higher rate of cases with sSMC in prenatals compared to newborn can be due to i) the bias caused by the maternal age effect in prenatal series, ii) the fact that prenatal diagnosis is sometimes performed due to known or suspected fetal pathology, and/or iii) severely affected fetuses may result in miscarriages and will therefore not be included among newborn cases. Recently, proof for all three suggested effects plus a further effect (4) have been observed. (Ad 1) A maternal age effect, which was suggested for all chromosomes (16) was demonstrated at least for sSMC derived from chromosome 15 (29) . (Ad 2 and 3) Prenatal diagnosis is performed also in a subset of fetuses which have suspect results in ultrasound and may result in miscarriages. This is the biological relevant subset which will not be seen in the newborn population. According to Kumar et al (30) 4.4% of sSMC pregnancies end in a stillbirth or spontaneous abortion. Also from the data summarized in Fig. 2 it is unlikely that this third effect takes place in a noteworthy proportion during the third trimester of pregnancy. If this would be the case in a significant rate, the percentage of de novo versus familial sSMC cases should decrease from early to later pregnancy. As shown in Fig. 2 this is not the case, with the rate remaining always more or less ~2 in cells of CVS, amniocytic fluid and newborn blood. (Ad 4) The last but numerically relevant 'bias' is the fact, that at present still 30-50% of pregnancies diagnosed with an sSMC fetus are terminated (2, 30, 31) , even though only 30% of sSMC cases manifest clinical symptoms (1) . This means that a certain percentage of potentially healthy children with sSMC are aborted.
In conclusion, no data is available on the 'real rate' of sSMC carriers in the prenatal human general population. What is available is the clinically relevant frequency of 0.075% for the prenatally studied human population. Through this study for the first time sound and reliable values for the frequency of sSMC in prenatal, infertility and dysmorphism diagnostics are available and can be related to the sSMC rate in the normal control population.
